Compare ATCH & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATCH | NNVC |
|---|---|---|
| Founded | 2022 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.6M | 33.7M |
| IPO Year | 2024 | 2008 |
| Metric | ATCH | NNVC |
|---|---|---|
| Price | $0.08 | $1.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $1.00 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 974.0K | 157.6K |
| Earning Date | 11-24-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.92 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $20,052,635.00 | N/A |
| Revenue This Year | $32.20 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.61 | ★ N/A |
| Revenue Growth | ★ 84.70 | N/A |
| 52 Week Low | $0.13 | $0.85 |
| 52 Week High | $0.38 | $1.93 |
| Indicator | ATCH | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 18.09 | 53.39 |
| Support Level | N/A | $1.23 |
| Resistance Level | $0.22 | $1.49 |
| Average True Range (ATR) | 0.01 | 0.10 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 13.87 | 59.26 |
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company is engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific antiviral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing. The Company's platform is based on host-mimicry and thereby has uniquely enabled the development of broad-spectrum antiviral drugs that the viruses would be unable to escape, a critical unmet need in antiviral therapeutics.